Clinical Trial Update: Single Dose Pharmacokinetic (PK) Study [Phase 1]

View source ↗

Summary

Healx AI completed a Phase 1 single-dose pharmacokinetic study evaluating an investigational therapy for Angelman Syndrome and Fragile X Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome
• Fragile Syndrome

Drugs mentioned

• Investigational therapy (unspecified)

Snippet

Sponsor: Healx AI | Conditions: Angelman Syndrome, Fragile X Syndrome | Phase 1 | Status: COMPLETED